中国临床药理学与治疗学2026，Vol.31Issue(4)：474-485,12.DOI:10.12092/j.issn.1009-2501.2026.04.006
慢性阻塞性肺疾病门诊患者的药物相关问题及其相关因素:一项横断面回顾性研究
Drug-related problems and its associated factors among outpatients with COPD:A cross sectional retrospective study
摘要
Abstract
AIM:Chronic obstructive pulmonary disease(COPD)is a globally prevalent condition,in-cluding a substantial patient population in China.However,data on drug-related problems(DRPs)among Chinese COPD outpatients remain scarce.This study aimed to investigate the types,causes,associated factors,and potential triggers of DRPs in COPD outpatients at a large general hospital in southern China.METHODS:With ethics committee approval,461 COPD patients prescribed at least one medication were enrolled in this retrospective study from September 2020 to November 2021.DRPs were identified and classified using the Pharmaceu-tical Care Network Europe(PCNE)DRP classification system(V9.10).Descriptive statistics,univariate analysis,and logistic regression were employed to explore potential risk factors for DRPs.RESULTS:A total of 239 DRPs with 567 underlying causes were identified.The most frequent DRP was"treatment effectiveness:insufficient effect"(91.2%,218/239).The leading causes were"no or inappropriate out-come monitoring"(31.0%,176/567)and"patient-related factors"(27.5%,156/567).Risk factors for DRPs included older age,current smoking,comor-bid bronchiectasis or silicosis,use of quinolone or lincosamide antibiotics,LABA+LAMA inhaler combi-nations,and a history of acute exacerbations.CONCLUSION:DRPs are common among Chinese COPD outpatients,primarily linked to suboptimal treatment effectiveness.Clinical pharmacists could play a crucial role in addressing these issues and im-plementing interventions in the future.关键词
药物相关问题/慢性阻塞性肺疾病/门诊患者/危险因素Key words
drug-related problems/chronic ob-structive pulmonary disease/outpatients/risk fac-tors分类
医药卫生引用本文复制引用
张佳娴,肖坚,黄行行,李梦瑶,鱼婷,于慧敏,李靖阳,宁磊,王莹..慢性阻塞性肺疾病门诊患者的药物相关问题及其相关因素:一项横断面回顾性研究[J].中国临床药理学与治疗学,2026,31(4):474-485,12.基金项目
湖南省自然科学基金(2025JJ80085) （2025JJ80085）
